PINK
DSKYF

Daiichi Sankyo Company Limited

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Daiichi Sankyo Company Limited Stock Price

Vitals

Today's Low:
$27.28
Today's High:
$28.91
Open Price:
$27.44
52W Low:
$22.0041
52W High:
$36.73
Prev. Close:
$28.9
Volume:
10900

Company Statistics

Market Cap.:
$65.84 billion
Book Value:
754.092
Revenue TTM:
$1,278.48 billion
Operating Margin TTM:
9.43%
Gross Profit TTM:
$691.56 billion
Profit Margin:
8.54%
Return on Assets TTM:
3.19%
Return on Equity TTM:
7.81%

Company Profile

Daiichi Sankyo Company Limited had its IPO on under the ticker symbol DSKYF.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Daiichi Sankyo Company Limited has a staff strength of 0 employees.

Stock update

Shares of Daiichi Sankyo Company Limited opened at $27.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $27.28 - $28.91, and closed at $28.74.

This is a -0.55% slip from the previous day's closing price.

A total volume of 10,900 shares were traded at the close of the day’s session.

In the last one week, shares of Daiichi Sankyo Company Limited have increased by 0%.

Daiichi Sankyo Company Limited's Key Ratios

Daiichi Sankyo Company Limited has a market cap of $65.84 billion, indicating a price to book ratio of 5.8531 and a price to sales ratio of 0.0568.

In the last 12-months Daiichi Sankyo Company Limited’s revenue was $1,278.48 billion with a gross profit of $691.56 billion and an EBITDA of $188.37 billion. The EBITDA ratio measures Daiichi Sankyo Company Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Daiichi Sankyo Company Limited’s operating margin was 9.43% while its return on assets stood at 3.19% with a return of equity of 7.81%.

In Q4, Daiichi Sankyo Company Limited’s quarterly earnings growth was a negative -10.8% while revenue growth was a positive 41.2%.

Daiichi Sankyo Company Limited’s PE and PEG Ratio

Forward PE
62.8931
Trailing PE
156.1364
PEG
31575.3

Its diluted EPS in the last 12-months stands at $0.22 per share while it has a forward price to earnings multiple of 62.8931 and a PEG multiple of 31575.3. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Daiichi Sankyo Company Limited’s profitability.

Daiichi Sankyo Company Limited stock is trading at a EV to sales ratio of 0.0515 and a EV to EBITDA ratio of 0.3815. Its price to sales ratio in the trailing 12-months stood at 0.0568.

Daiichi Sankyo Company Limited stock pays annual dividends of $30 per share, indicating a yield of 0.74% and a payout ratio of 0.38%.

Balance sheet and cash flow metrics

Total Assets
$2,398.03 billion
Total Liabilities
$457.07 billion
Operating Cash Flow
$0
Capital Expenditure
$17.59 billion
Dividend Payout Ratio
0.38%

Daiichi Sankyo Company Limited ended 2024 with $2,398.03 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2,398.03 billion while shareholder equity stood at $1,414.32 billion.

Daiichi Sankyo Company Limited ended 2024 with $0 in deferred long-term liabilities, $457.07 billion in other current liabilities, 50000000000.00 in common stock, $1,204.63 billion in retained earnings and $94.97 billion in goodwill. Its cash balance stood at $395.18 billion and cash and short-term investments were $795.19 billion. The company’s total short-term debt was $41,396,000,000 while long-term debt stood at $101.79 billion.

Daiichi Sankyo Company Limited’s total current assets stands at $1,437.61 billion while long-term investments were $0 and short-term investments were $400.01 billion. Its net receivables were $355.36 billion compared to accounts payable of $358.38 billion and inventory worth $266.69 billion.

In 2024, Daiichi Sankyo Company Limited's operating cash flow was $0 while its capital expenditure stood at $17.59 billion.

Comparatively, Daiichi Sankyo Company Limited paid $0.00 in dividends in 2024.

Other key metrics

Current Trading Price
$28.74
52-Week High
$36.73
52-Week Low
$22.0041
Analyst Target Price
$

Daiichi Sankyo Company Limited stock is currently trading at $28.74 per share. It touched a 52-week high of $36.73 and a 52-week low of $36.73. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $29.01 and 200-day moving average was $32.14 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 144.5% of the company’s stock are held by insiders while 5658% are held by institutions.

Frequently Asked Questions About Daiichi Sankyo Company Limited

The stock symbol (also called stock or share ticker) of Daiichi Sankyo Company Limited is DSKYF

The IPO of Daiichi Sankyo Company Limited took place on

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$0.21
-0.1
-33.55%
$39.86
-0.73
-1.8%
$74.46
0.15
+0.2%
$13.79
0.46
+3.45%
$76.8
-0.24
-0.31%
$10.41
0.14
+1.36%
$270.25
-7.5
-2.7%
Nuzee Inc (NUZE)
$7.71
0.02
+0.26%
Intuit Inc (INTU)
$546
-3.3
-0.6%
$1.48
-0.04
-2.63%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; and ferric carboxymaltose injection for treating anemia. It also provides edoxaban, an oral, once-daily, direct factor Xa inhibitor; esaxerenone and olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastases from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Address

3-5-1, Nihonbashi-honcho, Tokyo, Japan, 103-8426